{"pmid":32233972,"title":"Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic.","text":["Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic.","During this unprecedented time of extraordinary stress on the US healthcare system, the AHA/ASA Stroke Council-as individuals in our localities and together as an entity at the national level-acknowledge the mounting concern regarding optimal stroke care during the COVID-19 pandemic among vascular neurologists and those clinicians who care for patients with stroke. We therefore seek to provide guidance for the care of stroke patients in the midst of the crisis. Ordinarily, national recommendations go through a rigorous process of development, refinement, peer review, and thoughtful promulgation. None of that is possible at this time, yet we believe there is a substantial need for a broad policy statement that reflects both the commonality of the pandemic across the US and the individual variability necessary at local sites. We issue this temporary statement as an interim stopgap opinion, pending a more thorough and considered process.","Stroke","32233972"],"abstract":["During this unprecedented time of extraordinary stress on the US healthcare system, the AHA/ASA Stroke Council-as individuals in our localities and together as an entity at the national level-acknowledge the mounting concern regarding optimal stroke care during the COVID-19 pandemic among vascular neurologists and those clinicians who care for patients with stroke. We therefore seek to provide guidance for the care of stroke patients in the midst of the crisis. Ordinarily, national recommendations go through a rigorous process of development, refinement, peer review, and thoughtful promulgation. None of that is possible at this time, yet we believe there is a substantial need for a broad policy statement that reflects both the commonality of the pandemic across the US and the individual variability necessary at local sites. We issue this temporary statement as an interim stopgap opinion, pending a more thorough and considered process."],"journal":"Stroke","date":"2020-04-03T11:00:00Z","year":2020,"_id":"32233972","week":"202014|Mar 30 - Apr 05","doi":"10.1161/STROKEAHA.120.030023","keywords":["American Stroke Association","Corona Virus Disease 2019"],"source":"PubMed","locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"weight":0,"_version_":1662996001909112833,"score":7.6048946,"similar":[{"pmid":32233980,"title":"Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic.","text":["Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic.","Background and Purpose- Hyperacute assessment and management of patients with stroke, termed code stroke, is a time-sensitive and high-stakes clinical scenario. In the context of the current Coronavirus Disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus, the ability to deliver timely and efficacious care must be balanced with the risk of infectious exposure to the clinical team. Furthermore, rapid and effective stroke care remains paramount to achieve maximal functional recovery for those needing admission and to triage care appropriately for those who may be presenting with neurological symptoms but have an alternative diagnosis. Methods- Available resources, COVID-19-specific infection prevention and control recommendations, and expert consensus were used to identify clinical screening criteria for patients and provide the required nuanced considerations for the healthcare team, thereby modifying the conventional code stroke processes to achieve a protected designation. Results- A protected code stroke algorithm was developed. Features specific to prenotification and clinical status of the patient were used to define precode screening. These include primary infectious symptoms, clinical, and examination features. A focused framework was then developed with regard to a protected code stroke. We outline the specifics of personal protective equipment use and considerations thereof including aspects of crisis resource management impacting team role designation and human performance factors during a protected code stroke. Conclusions- We introduce the concept of a protected code stroke during a pandemic, as in the case of COVID-19, and provide a framework for key considerations including screening, personal protective equipment, and crisis resource management. These considerations and suggested algorithms can be utilized and adapted for local practice.","Stroke","Khosravani, Houman","Rajendram, Phavalan","Notario, Lowyl","Chapman, Martin G","Menon, Bijoy K","32233980"],"abstract":["Background and Purpose- Hyperacute assessment and management of patients with stroke, termed code stroke, is a time-sensitive and high-stakes clinical scenario. In the context of the current Coronavirus Disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus, the ability to deliver timely and efficacious care must be balanced with the risk of infectious exposure to the clinical team. Furthermore, rapid and effective stroke care remains paramount to achieve maximal functional recovery for those needing admission and to triage care appropriately for those who may be presenting with neurological symptoms but have an alternative diagnosis. Methods- Available resources, COVID-19-specific infection prevention and control recommendations, and expert consensus were used to identify clinical screening criteria for patients and provide the required nuanced considerations for the healthcare team, thereby modifying the conventional code stroke processes to achieve a protected designation. Results- A protected code stroke algorithm was developed. Features specific to prenotification and clinical status of the patient were used to define precode screening. These include primary infectious symptoms, clinical, and examination features. A focused framework was then developed with regard to a protected code stroke. We outline the specifics of personal protective equipment use and considerations thereof including aspects of crisis resource management impacting team role designation and human performance factors during a protected code stroke. Conclusions- We introduce the concept of a protected code stroke during a pandemic, as in the case of COVID-19, and provide a framework for key considerations including screening, personal protective equipment, and crisis resource management. These considerations and suggested algorithms can be utilized and adapted for local practice."],"journal":"Stroke","authors":["Khosravani, Houman","Rajendram, Phavalan","Notario, Lowyl","Chapman, Martin G","Menon, Bijoy K"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32233980","week":"202014|Mar 30 - Apr 05","doi":"10.1161/STROKEAHA.120.029838","keywords":["COVID-19","algorithms","consensus","pandemics","stroke"],"source":"PubMed","topics":["Diagnosis","Prevention"],"weight":1,"_version_":1662996001815789568,"score":416.02307},{"pmid":32233034,"title":"Overview of guidance for endoscopy during the coronavirus disease 2019 (COVID-19) pandemic.","text":["Overview of guidance for endoscopy during the coronavirus disease 2019 (COVID-19) pandemic.","From its beginning in December 2019, the COVID-19 outbreak has spread globally from Wuhan and is now declared a pandemic by the World Health Organization (WHO). The sheer scale and severity of this pandemic is unprecedented in the modern era. Though primarily a respiratory tract infection transmitted by direct contact and droplets, during aerosol generating procedures (AGPs) there is a possibility of airborne transmission. In addition, emerging evidence suggests possible fecal-oral spread of the virus. Clinical departments that perform endoscopy are faced with daunting challenges during this pandemic. To date, multiple position statements and guidelines have been issued by various professional organizations to recommend practices in endoscopic procedures. This article aims to summarize and discuss available evidence for these practices, to provide guidance for endoscopy to enhance patient safety, avoid nosocomial outbreaks, protect healthcare personnel and ensure rational use of personal protective equipment (PPE). Responses adapted to national recommendations, local infection control guidelines and tailored to the availability of medical resources are imminently needed to fight the COVID-19 pandemic.","J Gastroenterol Hepatol","Lui, Rashid N","Wong, Sunny H","Sanchez-Luna, Sergio A","Pellino, Gianluca","Bollipo, Steven","Wong, Mei-Yin","Chiu, Philip Wy","Sung, Joseph Jy","32233034"],"abstract":["From its beginning in December 2019, the COVID-19 outbreak has spread globally from Wuhan and is now declared a pandemic by the World Health Organization (WHO). The sheer scale and severity of this pandemic is unprecedented in the modern era. Though primarily a respiratory tract infection transmitted by direct contact and droplets, during aerosol generating procedures (AGPs) there is a possibility of airborne transmission. In addition, emerging evidence suggests possible fecal-oral spread of the virus. Clinical departments that perform endoscopy are faced with daunting challenges during this pandemic. To date, multiple position statements and guidelines have been issued by various professional organizations to recommend practices in endoscopic procedures. This article aims to summarize and discuss available evidence for these practices, to provide guidance for endoscopy to enhance patient safety, avoid nosocomial outbreaks, protect healthcare personnel and ensure rational use of personal protective equipment (PPE). Responses adapted to national recommendations, local infection control guidelines and tailored to the availability of medical resources are imminently needed to fight the COVID-19 pandemic."],"journal":"J Gastroenterol Hepatol","authors":["Lui, Rashid N","Wong, Sunny H","Sanchez-Luna, Sergio A","Pellino, Gianluca","Bollipo, Steven","Wong, Mei-Yin","Chiu, Philip Wy","Sung, Joseph Jy"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233034","week":"202014|Mar 30 - Apr 05","doi":"10.1111/jgh.15053","source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1662899337743564800,"score":199.87369},{"pmid":32245904,"title":"How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere.","text":["How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere.","New cases of the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. A few reports have showed that mortality due to SARS-CoV-2 is higher in elderly patients and other active comorbidities including cancer. To date, no effective treatment has been identified and management for critically ill patients relies on management in intensive care units. Patients with lung cancer are at risk of pulmonary complications from COVID-19. Furthermore, the use of chemotherapy might have a negative impact in patient's outcome. Therefore, the risk/benefit ratio of systemic anticancer treatment (SACT) has to be considered. For each patient, several factors including age and comorbidities, as well as the number of hospital visits for treatment, can influence this risk. Each hospital around the world has issued some internal policy guidelines for oncologists, aiming to limit risks during this difficult time. We hereby propose a tool to support oncologists and physicians in treatment decision for patients with lung cancer. There are several variables to consider, including the extent of the epidemic, the local healthcare structure capacity, the risk of infection to the individual, the status of cancer, patients' comorbidities, age and details of the treatment. Given this heterogeneity, we have based our suggestions bearing in mind some general factors There is not easy, universal solution to oncological care during this crisis and, to complicate matters, the duration of this pandemic is hard to predict. It is important to weigh the impact of each of our decisions in these trying times rather than rely on routine automatisms.","ESMO Open","Banna, Giuseppe","Curioni-Fontecedro, Alessandra","Friedlaender, Alex","Addeo, Alfredo","32245904"],"abstract":["New cases of the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. A few reports have showed that mortality due to SARS-CoV-2 is higher in elderly patients and other active comorbidities including cancer. To date, no effective treatment has been identified and management for critically ill patients relies on management in intensive care units. Patients with lung cancer are at risk of pulmonary complications from COVID-19. Furthermore, the use of chemotherapy might have a negative impact in patient's outcome. Therefore, the risk/benefit ratio of systemic anticancer treatment (SACT) has to be considered. For each patient, several factors including age and comorbidities, as well as the number of hospital visits for treatment, can influence this risk. Each hospital around the world has issued some internal policy guidelines for oncologists, aiming to limit risks during this difficult time. We hereby propose a tool to support oncologists and physicians in treatment decision for patients with lung cancer. There are several variables to consider, including the extent of the epidemic, the local healthcare structure capacity, the risk of infection to the individual, the status of cancer, patients' comorbidities, age and details of the treatment. Given this heterogeneity, we have based our suggestions bearing in mind some general factors There is not easy, universal solution to oncological care during this crisis and, to complicate matters, the duration of this pandemic is hard to predict. It is important to weigh the impact of each of our decisions in these trying times rather than rely on routine automatisms."],"journal":"ESMO Open","authors":["Banna, Giuseppe","Curioni-Fontecedro, Alessandra","Friedlaender, Alex","Addeo, Alfredo"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245904","week":"202014|Mar 30 - Apr 05","doi":"10.1136/esmoopen-2020-000765","keywords":["Editorial"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663169699672752130,"score":145.16449},{"pmid":32222812,"title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).","text":["Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).","BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which 4 are best practice statements, 9 are strong recommendations, and 35 are weak recommendations. No recommendation was provided for 6 questions. The topics were: (1) infection control, (2) laboratory diagnosis and specimens, (3) hemodynamic support, (4) ventilatory support, and (5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new recommendations in further releases of these guidelines.","Intensive Care Med","Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew","32222812"],"abstract":["BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which 4 are best practice statements, 9 are strong recommendations, and 35 are weak recommendations. No recommendation was provided for 6 questions. The topics were: (1) infection control, (2) laboratory diagnosis and specimens, (3) hemodynamic support, (4) ventilatory support, and (5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new recommendations in further releases of these guidelines."],"journal":"Intensive Care Med","authors":["Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222812","week":"202014|Mar 30 - Apr 05","doi":"10.1007/s00134-020-06022-5","keywords":["COVID-19","Clinical practice guidelines","Coronavirus","Critical illness","SARS CoV-2"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1662715354793639936,"score":142.57417},{"pmid":32224769,"title":"Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19).","text":["Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19).","BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which four are best practice statements, nine are strong recommendations, and 35 are weak recommendations. No recommendation was provided for six questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new evidence in further releases of these guidelines.","Crit Care Med","Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew","32224769"],"abstract":["BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which four are best practice statements, nine are strong recommendations, and 35 are weak recommendations. No recommendation was provided for six questions. The topics were: 1) infection control, 2) laboratory diagnosis and specimens, 3) hemodynamic support, 4) ventilatory support, and 5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new evidence in further releases of these guidelines."],"journal":"Crit Care Med","authors":["Alhazzani, Waleed","Moller, Morten Hylander","Arabi, Yaseen M","Loeb, Mark","Gong, Michelle Ng","Fan, Eddy","Oczkowski, Simon","Levy, Mitchell M","Derde, Lennie","Dzierba, Amy","Du, Bin","Aboodi, Michael","Wunsch, Hannah","Cecconi, Maurizio","Koh, Younsuck","Chertow, Daniel S","Maitland, Kathryn","Alshamsi, Fayez","Belley-Cote, Emilie","Greco, Massimiliano","Laundy, Matthew","Morgan, Jill S","Kesecioglu, Jozef","McGeer, Allison","Mermel, Leonard","Mammen, Manoj J","Alexander, Paul E","Arrington, Amy","Centofanti, John E","Citerio, Giuseppe","Baw, Bandar","Memish, Ziad A","Hammond, Naomi","Hayden, Frederick G","Evans, Laura","Rhodes, Andrew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224769","week":"202014|Mar 30 - Apr 05","doi":"10.1097/CCM.0000000000004363","source":"PubMed","topics":["Prevention","Diagnosis","Treatment"],"weight":1,"_version_":1662819280270393344,"score":142.34473}]}